Greg J. Fox: Levofloxacin’s safety for preventing multidrug-resistant TB
Greg J. Fox, Professor of Respiratory Medicine and Interim Director of Sydney Southeast Asia Centre at University of Sydney, shared a recent article on LinkedIn:
“Our landmark VQUIN trial published today in New England Journal of Medicine showed levofloxacin is safe for preventing multidrug-resistant tuberculosis.
Critically, the risk of developing TB was reduced by 60% at 54 weeks. This was shown in our pre-specified meta-analysis with the TB CHAMP Trial from South Africa in NEJM Evidence – also published today.
These findings led to new recent global Guidance from WHO recommending levofloxacin for treating TB infection among people at risk of MDR-TB.
Around the world, >400,000 households can now benefit from this new evidence each year.
Funded by National Health and Medical Research Council (NHMRC), and implemented through a wonderful collaboration between the Vietnam National Tuberculosis Program and Woolcock Institute of Medical Research.”
Title: A Meta-Analysis of Levofloxacin for Contacts of Multidrug-Resistant Tuberculosis
Authors: Trinh Duong, Joanna Brigden, H. Simon Schaaf, Paeds, Frances Garden, Ben J. Marais, Thu Anh Nguyen, Ian R. White, Diana M. Gibb, Nguyen Viet Nhung, Neil A. Martinson, Lee Fairlie, F.C.Paeds, Leonardo Martinez, Charlotte Layton, Andrea Benedetti, Guy B. Marks, Rebecca M. Turner, James A. Seddon, Anneke C. Hesseling, and Greg J. Fox for the TB-CHAMP and VQUIN MDR-TB trial teams
NEJM Group also shared a post on LinkedIn adding:
“In the report, investigators assessed the efficacy of levofloxacin for the prevention of secondary cases of tuberculosis among household contacts of persons with multidrug-resistant tuberculosis.”
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023